Page 2 - Eric Schoen News Today

1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimers disease dementia.Top-line results for on-going, 52-week Phase 3 trial expected approximately year-end...

Safety Finding Based on Blinded MRI Brain Data at Week 40ARIA is a Known Risk Factor for Anti-Amyloid Antibody DrugsMRI Data Presented at the 16th CTAD...

CUNY’s report makes no findings of data manipulation.The “egregious misconduct” cited in the report relates to internal record-keeping failures at CUNY.CUNY’s report finds that internal...

CUNY’s report makes no findings of data manipulation.The “egregious misconduct” cited in the report relates to internal record-keeping failures at...

Cassava bounced back from hitting a 52-week low to start the week.

804 Alzheimer’s Patients Are Enrolled in a Pivotal Phase 3 Clinical TrialA Second Pivotal Phase 3 Clinical Trial Is Expected to Complete Enrollment Q4 2023, With a Target Enrollment of Approximately...

An Independent Data and Safety Monitoring Board Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical Trials.The DSMB Recommended the Phase 3 Trials of...

An Independent Data and Safety Monitoring Board (DSMB) Recently Evaluated the Interim Patient Safety Database for Simufilam in On-Going Phase 3 Clinical...

AUSTIN, Texas, Sept. 06, 2023 -- Cassava Sciences, Inc. , a biotechnology company committed to the treatment of Alzheimer’s disease dementia, today announced that it has been invited to present...

Camp Kee Tov in Berkeley is saying goodbye to longtime song leader Eric Schoen and welcoming in Sasha Price.